Of all the industries Bangladesh has built since independence, pharmaceuticals may be the most quietly remarkable. A country that once imported most of its medicines, at prices set by foreign companies, now makes about 98 percent of the medicines its 170 million people consume, and sells the surplus to more than 150 countries, including the United States, Britain and the European Union. Its drugmakers produce cancer medicines, insulin and vaccines at prices the world's poorest patients can reach, and the sector is routinely described as the country's most promising export industry after garments. The foundations were laid by one policy decision in 1982 and one international exemption that is now, finally, running out.
Pharmaceutical Industry at a Glance
- Domestic market: about Tk 40,885 crore a year (IQVIA, year to mid-2026), growing at around 10 percent annually; more than US$3.5 billion
- Self-sufficiency: local companies meet about 98 percent of domestic demand; only about 2 percent of medicines are imported as finished products
- Companies: around 284 registered manufacturers; the top 10 hold roughly 70 to 75 percent of the market, and the top five more than half
- Leaders (IQVIA, FY2025): Square Pharmaceuticals (about 17.4 percent), Incepta (12.8 percent), Beximco (9.6 percent), Healthcare Pharmaceuticals (7.7 percent), then Renata
- Exports: US$213 million in FY2024-25, up from US$44 million in FY2010-11; the first ten months of FY2025-26 brought US$195 million, on pace for a record near US$250 million; medicines go to more than 150 countries
- The weakness: about 85 percent of active pharmaceutical ingredients (APIs), the raw materials, are imported, at a cost of roughly US$1.3 to 1.5 billion a year
- The deadline: the TRIPS patent waiver that underpins the model now runs to Bangladesh's deferred LDC graduation on 24 November 2029
The 1982 Turn
Before 1982, the market belonged to multinational companies, which held about three-quarters of sales and concentrated on profitable, often non-essential products: tonics, vitamins and branded remedies, while essential medicines were expensive or scarce. The National Drug Policy of 1982, enacted through the Drugs (Control) Ordinance, changed the rules overnight. Around 1,700 products judged non-essential or harmful were banned; the manufacture of simple products such as antacids and vitamins was reserved away from the multinationals; an essential drugs list of roughly 150 medicines became the core of the market, under price control; and foreign companies were pushed toward high-technology products or out. Local firms, many of them small, filled the space at once. Within a decade the balance of the industry had inverted, and the policy, criticised at the time by the multinationals and praised ever since by public health specialists, became the founding charter of the modern industry. Bangladesh's approach was later studied by other developing countries as a model of how a poor country could take charge of its own medicine supply.
The policy had an author. Its intellectual architect was Dr Zafrullah Chowdhury, the freedom fighter and founder of the Gonoshasthaya Kendra health movement, who had seen at first hand how the multinational drug trade failed poor patients and who pressed the essential-drugs logic on the government of the day. Gonoshasthaya's own pharmaceutical arm, founded in 1981, practised what the policy preached, making quality generics cheaply. The 1982 settlement, essential medicines first, prices controlled, local makers protected while they learned, held for four decades, and every major company in the industry today grew up inside it.
The Industry Today
The market that grew from that charter is large, concentrated and still expanding at about 10 percent a year, driven by population, rising incomes and the spread of chronic diseases such as diabetes and heart disease. Square Pharmaceuticals, founded in 1958 by Samson H. Chowdhury and now the country's largest drugmaker with about 17 percent of the market, makes around a thousand products and was the first Bangladeshi company to export medicines, in 1987; it now sells in 42 countries and runs a plant in Kenya. Incepta, founded only in 1999, climbed to second place on aggressive generics and vaccines. Beximco Pharmaceuticals, third at home, is the country's largest exporter and was the first Bangladeshi drugmaker to win approval from the United States Food and Drug Administration and sell in the American market. Renata, Healthcare, Eskayef, ACI, the Acme Laboratories, Aristopharma and Beacon, the oncology specialist, complete a top tier whose leading firms are listed on the Dhaka and Chittagong stock exchanges and audited to international standards. The product range has moved steadily up the ladder of difficulty: from tablets and syrups to inhalers, injectables, insulin, biosimilars, vaccines and targeted cancer therapies that sell for a fraction of their Western prices.
Regulation sits with the Directorate General of Drug Administration, which licenses manufacturers and products and administers price controls on essential medicines; an updated essential drugs list in 2026 extended official price setting to nearly 300 medicines. The system's strains are equally documented: a long tail of small firms of uneven quality, periodic concerns about substandard products, and the out-of-pocket reality that most medicine in Bangladesh is bought directly by patients, so every price movement lands on households.
The industry is also a major employer and a skills engine, commonly estimated at around 200,000 jobs across manufacturing, quality control, distribution and the pharmacy trade, and it sustains the country's pharmacy and chemistry graduates with the best industrial careers available to them. Its factories, concentrated around Dhaka, Gazipur, Narayanganj and Chittagong, run to the good manufacturing practice standards that regulated export markets demand, audited by foreign regulators as well as the DGDA. That combination, low costs, deep process chemistry skills and a huge home market to practise on, is the industry's real competitive asset, more durable than any single policy.
The pandemic gave the industry its global audition. In May 2020 Beximco launched the world's first generic version of remdesivir, the antiviral then at the centre of COVID-19 treatment, and Bangladeshi firms supplied medicines and, later, locally filled and produced vaccines through the pandemic years, even as the country's dependence on imported vaccine supplies from India was painfully exposed when exports were halted. The episode cut both ways: it proved the industry's speed and competence to the world, and it underlined how much of its raw material base still sits outside its borders.
Exports: From Nothing to 150 Countries
Exports began in the mid-1980s and for decades were a sideline. Export Promotion Bureau figures tell the acceleration plainly: US$44.2 million in FY2010-11, rising almost every year to US$213.16 million in FY2024-25, with the first ten months of FY2025-26 already at US$194.63 million, up 9.7 percent year on year, and the industry closing on its first US$250 million year. Three companies, Beximco, Incepta and Square, account for nearly half of all pharmaceutical exports, and around 1,200 Bangladeshi products received export registration in the past two years alone. The destination list, more than 150 countries, spans Asia, Africa and Latin America, and, increasingly, the regulated markets of North America, Britain, Australia and the EU, where approvals are hardest to win and margins best. Industry leaders argue, with some justice, that pharmaceuticals could in time become the country's second great export industry; the honest caveat is scale, since at a quarter of a billion dollars exports are still barely 6 percent of what the industry sells at home.
The API Weakness
For all its finishing strength, the industry begins abroad. About 85 percent of the active pharmaceutical ingredients, the chemicals that make a tablet work, are imported, mainly from China and India, at a cost estimated between US$1.3 and 1.5 billion a year; by value, raw materials account for 40 to 60 percent of the cost of making a medicine. The designated answer, an API industrial park at Gazaria in Munshiganj, has been under development for well over a decade and has been slowed by land, gas, effluent treatment and regulatory delays; only part of the planned capacity is in production. The industry association estimates that with proper finance and incentives, local plants could meet 30 to 40 percent of API demand. Local production is not zero: a small number of firms, among them Square, Beximco and Renata and specialist producers such as Active Fine Chemicals, already manufacture selected ingredients, and several large drugmakers have built or are building API units of their own. But the base remains narrow against the hundreds of molecules the industry consumes, and until it widens, the sector's celebrated self-sufficiency has an asterisk: Bangladesh makes its own medicines, largely from other countries' chemicals, and every disruption in that supply, as the pandemic years showed, is felt within weeks.
The Patent Cliff, Deferred
The industry's second foundation is legal. As a least developed country, Bangladesh is exempt under the WTO's TRIPS agreement from granting patents on pharmaceutical products, an exemption the WTO has extended to 2033 for countries that remain LDCs. That waiver is what allows Bangladeshi firms to manufacture modern patented medicines, cancer drugs, antiretrovirals, insulin and biologics, legally and royalty-free, and it is written into domestic law: the Patents Act 2023 keeps pharmaceutical products unpatentable for as long as Bangladesh remains an LDC, while adding TRIPS flexibilities such as compulsory licensing. The waiver was due to fall away with LDC graduation on 24 November 2026. On 29 October 2026, however, the United Nations General Assembly unanimously deferred the graduation of Bangladesh and Nepal by three years, to 24 November 2029, and the patent shield moved with it.
The deferral is a reprieve, not a rescue. Estimates of the industry's exposure vary, with analysts putting still-patented products at somewhere between 5 and 20 percent of local production, concentrated in exactly the high-value segments, oncology, diabetes and biologics, where the industry is heading. A medicine registered before graduation can generally continue; a new one launched too late may need a licence and royalties, or be barred. The industry's task for the three bought years is therefore specific: register what can be registered, build the API base, deepen biosimilar and research capacity, and prepare licensing and patent expertise for a world in which the exemption is gone. Bangladesh's drug industry was created by a country deciding its medicines mattered; whether it keeps its place will be decided the same way. Success, on the industry's own telling, would look like this by 2029: a working API base supplying a third or more of its ingredients, a shelf of biosimilars and complex generics registered at home and in regulated markets abroad, and export earnings several times today's, so that graduation day changes the industry's legal weather without changing its trajectory.
Sources
Export Promotion Bureau export data as reported by The Financial Express (June 2026); IQVIA market data for FY2025 and the year to mid-2026 as reported by BRAC EPL and industry publications; New Age and The Business Standard analyses of the drug industry, the API park and LDC graduation; United Nations General Assembly decision of 29 October 2026 deferring Bangladesh's LDC graduation to 24 November 2029; company reporting of Square, Beximco and Incepta Pharmaceuticals.